In agreement with its critical role in driving aggressive type of CLL, co-expression of RPS15 mutation and TP53 deletion in murine B cells altered translation and MYC activation and led to the onset of B cell malignancy with a shortened latency compared to mice with RPS15 mutation alone[43]. The gene discussed is MYC; the disease is B-cell chronic lymphocytic leukemia.